Skip to content
naulon
Not checkedNot checked for notices yet.

Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis

Hiromichi Shimizu, Toshimitsu Fujii, Shuji Hibiya and 7 more

Intestinal Research · 2021

doi:10.5217/ir.2020.00030 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

UC who had started TOF treatments between May and November 2018.The observation periods lasted up to 52 weeks after TOF administration.Patients were refractory to multiple treatments, such as corticosteroids, biologic agents, and a calcineurin inhibitor.TOF was initiated at 20 mg a day and decreasing to 10 mg a day after 8 weeks or more.All immunesuppressive agents, such as corticosteroids, immunomodulators, biologic agents, and calcineurin inhibitors, were withdrawn before starting TOF treatment.Disease activity was evaluated using the partial Mayo score (pMS), and laboratory data were collected at 4, 8, 12, 24, and 52 weeks after TOF administration.Our primary outcome was the clinical remission rate at 52 weeks; we also analyzed treatment efficacy and adverse events.We defined remission as pMS ≤ 2 without individual subscores > 1, response as a decrease of pMS by at least 2, and meeting one of the following conditions: (1) a decrease of the bleeding subscore by at least 1; (2) bleeding subscore < 1; or (3) above-defined remission induced.6,7 Failure was defined as TOF discontinuation due to symptom recurrence in patients in remission, nonresponse to TOF treatment, and serious adverse events.8 Differences in medians between the groups were compared using a non-parametric (Mann-Whitney), and comparisons between categorical variables were performed using chi-square test.TOF discontinuation-free survival was calculated.Kaplan-Meier curves were drawn for each subgroup and compared with log-rank (Mantel-Cox) test.SPSS version 26 (IBM Corp., Armonk, NY, USA) was used for statistical analysis, and the significant threshold was 0.05.

Abstract licence: CC BY-NC

References11

  1. 7.

10 more references, whose wording the paper’s licence keeps private.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.